Genor Biopharma Holdings Limited ( (HK:6998) ) has shared an update.
Genor Biopharma Holdings Limited has announced the postponement of its Extraordinary General Meeting (EGM) initially scheduled for February 13, 2025, to February 19, 2025. This delay is to provide additional time for including necessary information in the circular regarding a proposed change of auditor. Consequently, the period for closure of the company’s register of members has also been adjusted to coincide with this new date, affecting stakeholders’ ability to transfer shares and participate in the meeting.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a company incorporated in the Cayman Islands, operating within the biopharmaceutical industry. The company is primarily focused on the development and commercialization of innovative biologic therapies, addressing significant medical needs in the market.
YTD Price Performance: 12.63%
Average Trading Volume: 20,382
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €122.1M
For detailed information about 6998 stock, go to TipRanks’ Stock Analysis page.